
Marta Jimenez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9790876/publications.pdf Version: 2024-02-01



MADTA LIMENEZ

#	Article	IF	CITATIONS
1	Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis. Cancer Research, 2022, 82, 974-985.	0.9	14
2	Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial. Clinical Cancer Research, 2022, 28, 4018-4026.	7.0	4
3	Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. Nature Medicine, 2021, 27, 250-255.	30.7	85
4	A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). European Journal of Cancer, 2021, 158, 169-180.	2.8	9
5	Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. European Journal of Cancer, 2021, 159, 283-295.	2.8	24
6	Genomic characterization of metastatic breast cancers. Nature, 2019, 569, 560-564.	27.8	448
7	CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies from French OS2006 phase 3 trial. Oncolmmunology, 2017. 6, e1331193.	4.6	141
8	Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients. Oncotarget, 2017, 8, 83570-83584.	1.8	18
9	Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive nonâ€metastatic breast cancer. British Journal of Clinical Pharmacology, 2016, 81, 941-948.	2.4	24
10	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncology, The, 2014, 15, 267-274.	10.7	351